Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2012

BioLineRx Nabs Rights to Genoscience’s Early-Stage HCV Therapy

  • BioLineRx negotiated a worldwide, exclusive license to French firm Genoscience’s hepatitis C therapy candidate BL-8020. The license effectively marks BioLineRx’ entry into the growing HCV therapeutics market, which the firm says is already worth an estimated $6.5 billion annually.

    BL-8020 is an orally administered drug developed to inhibit HCV-induced autophagy, which represents a mechanism of action that differs from currently used anti-HCV drugs, Genoscience claims. Preclinical safety and efficacy testing suggested the candidate demonstrated synergistic activity when administered in combination with other anti-HCV drugs.

    Existing treatments for HCV are characterized by severe side effects, long treatment duration, and the development of resistance, remarks Kinneret Savitsky, Ph.D., BioLineRx CEO. “In these respects, BL-8020 has demonstrated a safety and efficacy profile, may shorten therapy duration, and may combat resistance by acting as an add-on platform which can potentially be combined with other oral hepatitis C therapies to increase their efficacy.”

    Genoscience is focused on the development of drugs against viral diseases such as HCV. To this end the firm is exploiting a technology platform that combines expertise in drug resistance with molecular modeling using its GenMol™ software, to enable the design of highly targeted molecules that will bypass drug resistance issues. 



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »